Initially 2.5–5 mg daily, adjusted according to response; maximum 20 mg daily; up to 15 mg may be given as a single dose before breakfast; higher doses divided
20 to 50     : Initially 2.5 mg daily. Titrate according to response
10 to 20     : Initially 2.5 mg daily. Titrate according to response
<10           : Initially 2.5 mg daily. Titrate according to response
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unlikely to be dialysed. Dose as in GFR <10 mL/min
HD                     :Unlikely to be dialysed. Dose as in GFR <10 mL/min
HDF/high flux   :Unlikely to be dialysed. Dose as in GFR <10 mL/min
CAV/VVHD      :Unlikely to be dialysed. Dose as in GFR 10 to 20 mL/min
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Analgesics: effects enhanced by NSAIDs
Antibacterials: effects enhanced by chloramphenicol, sulphonamides, and trimethoprim; effect reduced by rifamycins
Anticoagulants: effect possibly enhanced by coumarins; also possibly changes to INR
Antifungals: concentration increased by fluconazole, posaconazole and miconazole and possibly voriconazole – avoid with miconazole
Ciclosporin: may increase ciclosporin levelsSulfinpyrazone: enhanced effect of sulphonylureas
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
–
OTHER INFORMATION
Company does not recommend the use of Glibenese in patients with renal insufficiencyRenal or hepatic insufficiency may cause elevated blood levels of glipizide (increased risk of serious hypoglycaemic reactions).